Zhongmin Wang

9PUBLICATIONS
36CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 12, 2026
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

|Apr 07, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Shuang Huang, Feng Liu, Song Qu

|Mar 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Yang Sun, Hongying Yang, Jing Wang

|Mar 27, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Lin Shen, Yanqiao Zhang, Ziyu Li

|Jan 22, 2025
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Lin Shen, Yanqiao Zhang, Ziyu Li

|Jun 18, 2024
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.

Xiaozhong Chen, Wei Wang, Qingfeng Zou

Pageof 2

Frequent Collaborators

3 joint publications

Jiafu Ji

3 joint publications

Ziyu Li

3 joint publications

Lin Shen

3 joint publications

Xiangyu Gao